NGL Fine-Chem Limited commenced commercial production of Phase II of its greenfield facility in Tarapur, Maharashtra, on September 24, 2026. This milestone completes the full commissioning of the expansion project, which involved a total investment of ₹222 crore.

The development follows the earlier commencement of Phase I on March 11, 2025. The company stated that the phased approach was designed to augment manufacturing infrastructure and support its diverse portfolio of active pharmaceutical ingredients (APIs). With both phases now operational, the facility is fully functional.

Capacity and product flexibility

NGL Fine Chem noted that aggregate installed capacity cannot be expressed as a single uniform quantity, such as tonnes per annum. This is because the company manufactures a wide variety of APIs, each requiring different manufacturing processes, batch sizes, cycle times, yields, and equipment. Consequently, actual production capacity varies significantly depending on the specific product mix and the type of API manufactured.

The new capacity addition is intended to be utilised flexibly across the company's diverse API product portfolio. Utilisation will depend on product requirements, manufacturing schedules, and available plant and equipment resources. The company will continue to disclose quantitative production or capacity information only where such data is relevant and meaningfully determinable for specific APIs or product categories.

Financing structure

The project was financed through a combination of internal accruals and external debt. The table below details the financing breakdown and key project metrics disclosed in the regulatory filing.

What the numbers show

The financing structure reveals a significant reliance on internal cash generation to fund capital expenditure. Internal accruals accounted for ₹138 crore, representing approximately 62% of the total ₹222 crore investment. In contrast, term loans from banks contributed ₹84 crore, or roughly 38% of the funding mix. This high proportion of internal funding suggests robust cash flow generation from existing operations, reducing dependency on external leverage for this expansion phase.

The filing confirms that the company operates under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation regarding the commencement of commercial production has been filed with BSE and NSE, ensuring transparency for stakeholders regarding the operational status of the new infrastructure.

NGL Fine Chem confirmed the conclusion of its scheduled virtual one-to-one meeting with an analyst on September 16, 2026. The company disclosed that the session proceeded as planned without any presentation or sharing of unpublished price-sensitive information.

The disclosure was filed with both the BSE Limited and the National Stock Exchange of India Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This filing serves as the official outcome report for the engagement previously intimated on September 10, 2026.

Meeting Outcome

The company clarified that only information already available in the public domain was discussed during the interaction. No new financial data or strategic updates were released during the call.

Compliance Notes

Shivam Gharat, Company Secretary and Compliance Officer, signed the disclosure dated September 16, 2026. He reaffirmed that no Unpublished Price Sensitive Information (UPSI) pertaining to the company was shared with the analysts or investors during the meet.